Weight Loss Can Improve Health, and Awareness Helps Keep the Journey Safe

GLP-1 medications have become an important part of care for many people living with obesity or type 2 diabetes. Drugs such as semaglutide and tirzepatide may support meaningful weight loss and better metabolic health when prescribed and monitored appropriately.

As with any widely used treatment, greater use has also brought greater attention to possible side effects and related health questions. One of those questions concerns the gallbladder. The purpose of this article is not to create fear or suggest that a problem will occur. It is to explain a possible association, place the available evidence in context, and help readers recognize when a new symptom deserves professional attention.

What the Research Suggests, and What It Does Not Prove

Rapid weight loss has long been recognized as one factor associated with gallstone formation, including after very low calorie diets and bariatric surgery. The NIDDK explains that losing weight quickly may increase cholesterol in bile and may affect normal gallbladder emptying. [2]

Research has also examined whether GLP-1 medications are associated with gallbladder or biliary conditions. A systematic review involving 76 randomized clinical trials and more than 103,000 participants observed a higher relative occurrence of these conditions among people assigned to GLP-1 receptor agonists. The association appeared stronger in trials focused on weight loss, at higher doses, and with longer treatment periods. [1]

These findings are indicators from combined study populations. They do not establish that every person taking a GLP-1 medication will develop gallstones, nor do they determine what caused a symptom in an individual patient. Personal risk may be influenced by many factors, including prior gallstones, rate of weight loss, age, diet, family history, metabolic health, and other medical conditions. The evidence should support awareness and informed conversation, not alarm or self-diagnosis.

Symptoms Are Signals, Not Diagnoses

Digestive symptoms such as nausea, fullness, constipation, diarrhea, or general abdominal discomfort may occur during GLP-1 treatment. Similar symptoms can also arise from food, dehydration, infection, reflux, gallstones, or many unrelated conditions. A symptom alone cannot establish the cause. [3,4]

Gallbladder-related problems are often associated with pain in the upper right or upper middle abdomen. The discomfort may sometimes spread toward the back or right shoulder and may be accompanied by nausea or vomiting. Some people notice episodes after meals, while others experience a less predictable pattern.

The practical message is simple: new, persistent, intense, or recurring abdominal pain should not automatically be labeled as a medication side effect. It deserves an individualized assessment, particularly when it interferes with eating, hydration, sleep, or normal activities.

When Not to Wait

Some symptoms call for prompt medical attention regardless of whether a person uses a GLP-1 medication. These include:

• Severe or persistent abdominal pain
• Fever or chills with abdominal pain
• Yellowing of the eyes or skin
• Repeated vomiting or inability to keep fluids down
• Fainting, confusion, marked weakness, or rapid worsening

These warning signs can occur in several urgent conditions. The safest response is timely evaluation rather than attempting to determine the diagnosis at home.

Why Individual Evaluation Matters

Abdominal symptoms can overlap, and the same complaint may have different explanations in different people. For that reason, decisions about testing or treatment should be based on the complete clinical picture rather than on a medication name or an online checklist.

A qualified clinician can determine whether observation, medication review, laboratory testing, imaging, or referral is appropriate. Not every symptom requires an extensive investigation, and not every gallstone requires treatment. The appropriate next step depends on the individual circumstances. [5,6]

Gallstones Do Not Always Mean Surgery

Gallstones are sometimes discovered in people who have no symptoms, and many of those cases do not require an operation. Treatment becomes a more relevant discussion when symptoms recur or when complications are present.

When surgery is recommended, minimally invasive gallbladder removal is a well-established option, but the indication, timing, expected recovery, and alternatives must be individualized. General recovery estimates are useful for education, but they are not promises for a particular patient. [7,8]

Medication Decisions Belong in a Clinical Conversation

A published article should never be used as a reason to stop, restart, skip, or change a prescribed medication. GLP-1 treatment may provide substantial benefits, and any decision about its use should consider the reason it was prescribed, current symptoms, metabolic control, treatment goals, and the risks of interruption.

People planning a procedure should make sure the surgical and anesthesia teams know all medications they use. Guidance concerning GLP-1 drugs in the perioperative period continues to evolve, which reinforces the importance of following current, individualized instructions rather than a permanent rule published online. [3,9]

A Balanced Approach During Weight Loss

A few habits can make health changes easier to discuss and monitor:

• Keep scheduled follow-up appointments
• Report new or recurring symptoms instead of assuming their cause
• Avoid adding extreme calorie restriction without professional guidance
• Maintain adequate hydration
• Follow the nutrition plan established with the treating clinician
• Keep an updated list of medications and dose changes

These steps do not guarantee prevention of gallstones or other complications. They simply support continuity of care and better-informed decisions.

A South Florida Note

Heat and humidity make hydration especially important in Palm Beach and Broward County. Reduced food intake, nausea, or vomiting may become harder to tolerate during hot weather. Hydration remains important, but it should not be treated as a substitute for medical evaluation when symptoms are severe, persistent, or worsening.

The Bottom Line

GLP-1 medications are valuable treatments for many patients. Research has identified an association between these medications, rapid weight loss, and gallbladder or biliary events in some study populations, but those findings should be understood as indicators, not as predictions for every individual.

The balanced message is to remain informed without becoming alarmed. Do not change prescribed treatment without guidance, do not assume that every digestive symptom is caused by the medication, and do not ignore pain or warning signs that persist or worsen. Medical knowledge and clinical guidance evolve, so individual decisions should always be based on current evidence and a direct conversation with the appropriate healthcare professional.

To schedule a consultation with Dr. Mann, visit drmannsurgery.com or call our office directly.

References and Clinical Sources

1. He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine. 2022;182(5):513–519. PubMed · Full text
2. National Institute of Diabetes and Digestive and Kidney Diseases. Dieting and Gallstones. Explains the relationship among rapid weight loss, additional cholesterol in bile, impaired gallbladder emptying, and gallstone formation. NIDDK
3. U.S. Food and Drug Administration. WEGOVY, semaglutide, Prescribing Information. See warnings concerning acute gallbladder disease, gastrointestinal adverse reactions, delayed gastric emptying, and pulmonary aspiration during anesthesia or deep sedation. FDA prescribing information
4. National Institute of Diabetes and Digestive and Kidney Diseases. Gallstones: Definition, Symptoms, and Causes. NIDDK
5. American College of Radiology. ACR Appropriateness Criteria: Right Upper Quadrant Pain, 2022 Update. Evidence-based guidance on ultrasound and subsequent imaging for suspected biliary disease. ACR
6. National Institute of Diabetes and Digestive and Kidney Diseases. Diagnosis of Gallstones. NIDDK
7. National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for Gallstones. NIDDK
8. Society of American Gastrointestinal and Endoscopic Surgeons. Gallbladder Removal Surgery, Cholecystectomy: Patient Information. Includes same-day discharge and typical return-to-activity guidance after laparoscopic surgery. SAGES
9. Kindel TL, Wang AY, Wadhwa A, et al. Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-Like Peptide-1 Receptor Agonists in the Perioperative Period. Clinical Gastroenterology and Hepatology. Published online 2024. DOI: 10.1016/j.cgh.2024.10.003. Full text

Sources accessed August 1, 2026.

Medical disclaimer: This article is general education and not medical advice. Do not stop or change a prescribed medication without speaking with the clinician managing your treatment. For a diagnosis and individualized recommendations, schedule a consultation.